<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of Modern Oncology</journal-id><journal-title-group><journal-title xml:lang="en">Journal of Modern Oncology</journal-title><trans-title-group xml:lang="ru"><trans-title>Современная онкология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1815-1434</issn><issn publication-format="electronic">1815-1442</issn><publisher><publisher-name xml:lang="en">LLC Obyedinennaya Redaktsiya</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">34956</article-id><article-id pub-id-type="doi">10.26442/18151434.2020.2.200103</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Review</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзор</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Biobanks in oncology: global experience and Russian reality</article-title><trans-title-group xml:lang="ru"><trans-title>Биобанки в онкологии: мировой опыт и российская действительность</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8784-8415</contrib-id><name-alternatives><name xml:lang="en"><surname>Kaprin</surname><given-names>Andrei D.</given-names></name><name xml:lang="ru"><surname>Каприн</surname><given-names>Андрей Дмитриевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof., Acad. RAS</p></bio><bio xml:lang="ru"><p>акад. РАН, д-р мед. наук, проф., ген. дир</p></bio><email>grivtsova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7689-6032</contrib-id><name-alternatives><name xml:lang="en"><surname>Ivanov</surname><given-names>Sergei A.</given-names></name><name xml:lang="ru"><surname>Иванов</surname><given-names>Сергей Анатольевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф. РАН, дир.</p></bio><email>grivtsova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8580-933X</contrib-id><name-alternatives><name xml:lang="en"><surname>Petrov</surname><given-names>Vladimir A.</given-names></name><name xml:lang="ru"><surname>Петров</surname><given-names>Владимир Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, зав. научно-образовательным отд.</p></bio><email>grivtsova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7186-8531</contrib-id><name-alternatives><name xml:lang="en"><surname>Dukhova</surname><given-names>Natalia N.</given-names></name><name xml:lang="ru"><surname>Духова</surname><given-names>Наталья Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Res. Officer</p></bio><bio xml:lang="ru"><p>науч. сотр. лаб. клинической иммунологии</p></bio><email>grivtsova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Dvinskikh</surname><given-names>Nina Iu.</given-names></name><name xml:lang="ru"><surname>Двинских</surname><given-names>Нина Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, зав. отд. морфологии</p></bio><email>grivtsova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Falaleeva</surname><given-names>Natalia A.</given-names></name><name xml:lang="ru"><surname>Фалалеева</surname><given-names>Наталья Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, зав. отд-нием лекарственного лечения</p></bio><email>grivtsova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9103-9688</contrib-id><name-alternatives><name xml:lang="en"><surname>Grivtsova</surname><given-names>Liudmila Iu.</given-names></name><name xml:lang="ru"><surname>Гривцова</surname><given-names>Людмила Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Biol.)</p></bio><bio xml:lang="ru"><p>д-р биол. наук, зав. отд. лабораторной медицины</p></bio><email>grivtsova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Tsyb Medical Radiological Research Centre – branch of the National Medical Research Radiological Centre</institution></aff><aff><institution xml:lang="ru">Медицинский радиологический научный центр им. А.Ф. Цыба – филиал ФГБУ «Научный медицинский исследовательский центр радиологии» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-06-30" publication-format="electronic"><day>30</day><month>06</month><year>2020</year></pub-date><volume>22</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>82</fpage><lpage>88</lpage><history><date date-type="received" iso-8601-date="2020-07-07"><day>07</day><month>07</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-07-07"><day>07</day><month>07</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://modernonco.orscience.ru/1815-1434/article/view/34956">https://modernonco.orscience.ru/1815-1434/article/view/34956</self-uri><abstract xml:lang="en"><p>One of the integral components of modern large-scale research projects in the field of medicine are biobanks. The main objective of this infrastructure is the professional collection of biological samples that can be studied with respect to a wide range of molecular biological parameters and will not lose their information value over a long storage period. These samples are made informative not only by correctly conducted preanalytical preparation at the stage of taking samples and placing them in storage, but also by detailed information support (the so-called annotated samples). The sample annotation is the fully collected personal, clinical and laboratory data about a patient. An important point of the biobank infrastructure is compliance with regulatory legal acts and ethical standards, including the procedure for signing an informed consent by a patient about voluntary donation of biological samples and the use of personal data. All this ensures the implementation of the main objective of creating biobanks – the wide and uninterrupted availability of collections of biological material for researchers and developers and compliance with specific scientific tasks. This review is devoted to biobanking issues, as well as to the description and analysis of the currently existing oncological biobank infrastructure, both globally and within the Russian Federation.</p></abstract><trans-abstract xml:lang="ru"><p>Одним из неотъемлемых компонентов современных масштабных исследовательских проектов в области медицины являются биобанки. Основная задача данной инфраструктуры – это профессиональный сбор биологических образцов, которые могут быть изучены в отношении широкого спектра молекулярно-биологических параметров и не потеряют своей информативности в течение длительного срока хранения. Информативными данные образцы делает не только правильно проведенная преаналитическая подготовка на этапе забора проб и их размещения в хранилища, но подробное информационное сопровождение (так называемое аннотированние образцов). Аннотация образца – это максимально полно собранные персональные, клинические и лабораторные данные о пациенте. Важным моментом инфраструктуры биобанка является соблюдение нормативно-правовых актов и этических норм, в том числе – процедуры подписания информированного согласия пациентом о добровольной дотации биологических образцов и использовании персональных данных. Все это обеспечивает осуществление основной цели создания биобанков – широкую и бесперебойную доступность коллекций биологического материала для исследователей и разработчиков и соответствие конкретным научным задачам. Данный обзор посвящен проблематике биобанкирования, а также описанию и анализу существующей на данный момент инфраструктуры биобанков онкологической направленности как на мировом уровне, так и в Российской Федерации.</p></trans-abstract><kwd-group xml:lang="en"><kwd>biobanks</kwd><kwd>infrastructure</kwd><kwd>biorepositories</kwd><kwd>biological material</kwd><kwd>research project</kwd><kwd>frozen tissue samples</kwd><kwd>paraffin blocks</kwd><kwd>biobanking</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>биобанки</kwd><kwd>инфраструктура</kwd><kwd>биорепозитарии</kwd><kwd>биологический материал</kwd><kwd>исследовательский проект</kwd><kwd>образцы замороженной ткани</kwd><kwd>парафиновые блоки</kwd><kwd>биобанкирование</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2019. [Malignant neoplasms in Russia in 2018 (morbidity and mortality). Eds. A.D. Kaprin, V.V. Starinskij, G.V. Petrova. Moscow, 2019 (in Russian).]</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol 2001; 10 (3): 139–52. DOI: 10.1097/00019606-200109000-00001</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Bazel R. Her-2: the making of Herceptin, a revolutionary treatment for breast cancer. Random House, 1998.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004; 101 (36): 13306–11. DOI: 10.1073/pnas.0405220101</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Каприн А.Д., Галкин В.Н., Жаворонков Л.П. и др. Синтез фундаментальных и прикладных исследований – основа обеспечения высокого уровня научных результатов и внедрения их в медицинскую практику. Радиация и риск. 2017; 26 (2): 26–37. [Kaprin A.D., Galkin V.N., Zhavoronkov L.P. et al. Sintez fundamental’nyh i prikladnyh issledovanij – osnova obespecheniya vysokogo urovnya nauchnyh rezul’tatov i vnedreniya ih v medicinskuyu praktiku. Radiaciya i risk. 2017; 26 (2): 26–37 (in Russian).]</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Riegman PH, Morente MM, Betsou F et al. Biobanking for better healthcare. Mol Oncol 2008; 2 (3): 213–22. DOI: 10.1016/j.molonc.2008.07.004</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Смирнова Ю. Банковское дело, как путь к персонифицированной медицине. Наука и жизнь. 2013; 1: 14. [Smirnova Iu. Bankovskoe delo, kak put’ k personifitsirovannoi meditsine. Nauka i zhizn’. 2013; 1: 14 (in Russian).]</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Fransson MN, Rial-Sebbag E, Brochhausen M et al. Toward a common language forbiobanking. Eur J Hum Genet 2015; 23 (1): 22–8. DOI: 10.1038/ejhg.2014.45</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Dawber TR, Kannel WB. The Framingham Study. An epidemiologic approach to coronary heart disease. Circulation 1966; 34 (4): 553–55. DOI: 10.1161/01.cir.34.4.553</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Asslaber M, Zatloukal K. Biobanks: transnational, European and global networks. Brief Funct Genom Proteomics 2007;6 (3): 193–201. DOI: 10.1093/bfgp/elm023.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Swede H, Stone CL, Norwood AR. National population-based biobanks for genetic research. Genet Med 2007; 9 (3): 141–9. DOI: 10.1097/gim.0b013e3180330039</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Mohamadkhani A, Poustchi H. Repository of Human Blood Derivative Biospecimens in Biobank: Technical Implications. Middle East J Dig Dis 2015; 7 (2): 61–8.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Andersson K, Bray F, Arbyn M et al. The interface of population-based cancer registries and biobanks in etiological and clinical research–current and future perspectives. Acta Oncol 2010; 49 (8): 1227–34. DOI: 10.3109/0284186X.2010.496792</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Elliott P, Peakman TC. The UK Biobank sample handlingand storage protocol for the collection, processing and archivingof human blood and urine. Int J Epidemiol 2008; 37 (2): 234–44. DOI: 10.1093/ije/dym276</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Paskal W, Paskal АM, Dębski Т et al. Aspects of Modern Biobank Activity – Comprehensive Review. Pathol Oncol Res 2018; 24: 771–85.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kofanova OA, Mommaerts K, Betsou F. Tube Polypropylene: A Neglected Critical Parameter for Protein Adsorption During Biospecimen Storage. Biopreserv Biobank 2015; 13 (4): 296–8. DOI: 10.1089/bio.2014.0082</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>ISO 20387:2018. https://www.iso.org/standard/67888.html</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Guerin JS, Murray DW, McGrath MM et al. Molecular medicine ireland guidelines for standardized biobanking. Biopreserv Biobank 2010; 8 (1): 3–63. DOI: 10.1089/bio.2010.8101</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Leitsalu L, Haller T, Esko T et al. Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. Int J Epidemiol 2015; 44 (4): 1137–47. DOI: 10.1093/ije/dyt268</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Zawati M, Borry P, Howard H et al. Closure of populationbiobanks and direct-to-consumer genetic testing companies. Hum Genet 2011; 130 (3): 425–32. DOI: 10.1007/s00439-011-1019-4</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Awadalla P, Boileau C, Payette Y et al. Cohort profile of the CARTaGENE study: Quebec’s population-based biobank for public health and personalized genomics. Int J Epidemiol 2013; 42 (5): 1285–99. DOI: 10.1093/ije/dys160</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Bonnelykke K, Sleiman P, Nielsen K et al. Agenome-wideas sociation study identifies CDHR3 asasus ceptibility locus for early childhoodasthm a with sever exacerbations. Nat Genet 2014; 46 (1): 51–5.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Haukkala A, Kujala E, Alha P et al. The return of unexpected research results in a biobankstudy and referral to health care for heritable long QT syndrome. Public Health Genomics 2013; 16 (5): 241–50. DOI: 10.1159/000354105</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Wood AR, Esko T, Yang J et al. Defining the role of common variation in the genomicand biological architecture of adult human height. Nat Genet 2014; 46 (11): 1173–86. DOI: 10.1038/ng.3097</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Reza M, Cox D, Phillips L et al. MRC Centre Neuromuscular Biobank (Newcastle and London): Supporting and facilitating rare and neuromuscular disease research worldwide. Neuromuscul Disord 2017; 27 (11): 1054–64. DOI: 10.1016/j.nmd.2017.07.001</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>De Souza YG, Greenspan JS Biobanking past, present and future: responsibilitie sand benefits. AIDS (London) 2013; 27 (3): 303–12. DOI: 10.1097/QAD.0b013e32835c1244</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Check Hayden E. Proposed Ebola biobank would strengthen African science. Nature 2015; 524 (7564): 146–7. DOI: 10.1038/524146a</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Riegman PH, Morente MM, Betsou F et al. Biobanking for better healthcare. Mol Oncol 2008; 2 (3): 213–22. DOI: 10.1016/j.molonc.2008.07.004</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Goebell PJ, Morente MM. New concepts of biobanks – strategic chance for uro-oncology. Urol Oncol 2010; 28 (4): 449–57. DOI: 10.1016/j.molonc.2008.07.004</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Ose J, Fortner RT, Schock H et al. Bueno-de-Mesquita HBetal Insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort. Br J Cancer 2015; 112 (1): 162–6. DOI: 10.1038/bjc.2014.566</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>McKenzie F, Ferrari P, Freisling H et al. Healthy life style and risk of breast cancer among postmenopausal women in the European Prospective Investigation into Cancerand Nutrition cohort study. Int J Cancer 2015; 136 (11): 2640–8. DOI: 10.1002/ijc.29315</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Engeset D, Braaten T, Teucher B et al. Fish consumption and mortality in the European Prospective Investigation into Cancer and Nutrition cohort. Eur J Epidemiol 2015; 30 (1): 57–70. DOI: 10.1007/s10654-014-9966-4</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Shui IM, Lindstrom S, Kibel AS et al. Prostate Cancer (PCa) Risk Variants and Risk of Fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Eur Urol 2014; 65 (6): 1069–75. DOI: 10.1016</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Schumacher FR, Olama AA, Berndt SI et al. Association analyses of more than 140,000 men identify 63 new prostate сancer susceptibility loci. Nat Genet 2018; 50 (7): 928–36. DOI: 10.1038/s41588-018-0142-8</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Erbas В, Provenzano Е, Armes J et al. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat 2006; 97 (2): 135–44. DOI: 10.1007/s10549-005-9101-z</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Peila R, Arthur R, Rohan TE. Risk factors for ductal carcinoma in situ of the breast in the UK Biobank cohort study. Cancer Epidemiol 2020; 64 (101648). doi.org/10.1016/j.canep.2019.101648</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Knuiman MW, Jamrozik K, Welborn TA et al. Age and secular trends in risk factors for cardiovascular disease in Busselton. Australian J Public Health 1995; 19 (4): 375–82. DOI: 10.1111/j.1753-6405.1995.tb00389.x</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Knuiman MW, Hung J, Divitini ML et al. Utility of the metabolic syndrome and its components in the prediction of incident cardiovascular disease: a prospective cohort study. Eur J Cardiovasc Prevention Rehabilitation 2009; 16 (2): 235–41. doi.org/10.1097/HJR.0b013e32832955fc</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Li M, Eastman CJ, Waite KV et al. Are Australian children iodine deficient? Results of the Australian National Iodine Nutrition Study. Med J Australia 2006; 184 (4): 165–9.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Chan YX, Matthew W. Knuiman et al. Lower TSH and higher free thyroxine predict incidence of prostate but not breast, colorectal or lung cancer. Eur J Endocrinol 2017; 177: 297–308.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Liao X, Lochhead P, Nishihara R et al. Aspirin Use, Тumor PIK3CA Mutation, and Colorectal-Cancer Survival. N Engl J Med 2012; 367 (17): 1596–606. DOI: 10.1056/NEJMoa1207756</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Betancourt LH, Szasz AM, Kuras M et al. The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma-Association with Clinical Outcome and Tumor Phenotypes. Cancers (Basel) 2019; 11 (12): 2–18. DOI: 10.3390/cancers11121981</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Lee YM, Grauffel C, Chen T et al. Factors Governing the Different Functions of Zn2+-Sites with Identical Ligands in Proteins. J Chem Inf Model 2019; 59 (9): 3946–54. DOI: 10.1021/acs.jcim.9b00617</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Haslacher H, Bayer M, Fiegl H et al. Quality management at the national biobanking level – establishing a culture of mutual trust and support: the BBMRI. at example. Clin Chem Lab Med 2019; 57 (12): 301–5. DOI: 10.1515/cclm-2019-0491</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Kozlakidis Z. Strides forward in biobanking ethics. Lancet Public Health 2019; 4 (10): 495. DOI: 10.1016/S2468-2667(19)30154-9</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Jang AY, Kim S, Park SJ et al. A Nationwide multicenter registry and biobank program for deep phenotyping of idiopathic and hereditary pulmonary arterial hypertension in Korea: the PAH platform for deep phenotyping in Korean subjects (PHOENIKS) cohort. Clin Hypertens 2019; 25 (21). DOI: 10.1186/s40885-019-0126-8</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Shin KH, Kim HH, Kwon BS et al. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis. Ann Lab Med 2020; 40 (1): 40–7. DOI: 10.3343/alm.2020.40.1.40</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Chernobyl Tissue Bank. https://www.chernobyltissuebank.com/</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Иванов С.А., Петров В.А., Гривцова Л.Ю. и др. Международный опыт создания и развития биобанков. Что мы возьмем в работу? Материалы итоговой научно-практической конференции «Радиация и организм». Обнинск, 2019; c. 62–5. [Ivanov S.A., Petrov V.A., Grivtsova L.Iu. et al. Mezhdunarodnyi opyt sozdaniia i razvitiia biobankov. Chto my voz’mem v rabotu? Materialy itogovoi nauchno-prakticheskoi konferentsii «Radiatsiia i organizm’. Obninsk, 2019; p. 62–5 (in Russian).]</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Гривцова Л.Ю., Духова Н.Н., Семенова Н.С. и др. Первые шаги по созданию отечественного сетевого онкобиобанка. Материалы итоговой научно-практической конференции «Радиация и организм». Обнинск, 2019; c. 41–3. [Grivtsova L.Iu., Dukhova N.N., Semenova N.S. et al. Pervye shagi po sozdaniiu otechestvennogo setevogo onkobiobanka. Materialy itogovoi nauchno-prakticheskoi konferentsii «Radiatsiia i organizm’. Obninsk, 2019; p. 41–3 (in Russian).]</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Семененко Т.А. Роль банка сывороток крови в системе биологической безопасности страны. Вестн. Росздравнадзора. 2010; 3: 55–8. [Semenenko T.A. Rol’ banka syvorotok krovi v sisteme biologicheskoi bezopasnosti strany. Vestn. Roszdravnadzora. 2010; 3: 55–8 (in Russian).]</mixed-citation></ref></ref-list></back></article>
